Thomas Wales’ Post

2024 is already shaping up to be a landmark year with groundbreaking FDA approvals. With the first half of the year aimed at cell & gene therapy, the second half of 2024 is equally thrilling with key FDA decisions on the horizon: 🧠 Eli Lilly and Company's donanemab for Alzheimer's - promising better cognitive outcomes. 💪 Adaptimmune’s afami-cel for synovial sarcoma - a potential game-changer in T cell therapy. 💊 Lykos Therapeutics’ MDMA for PTSD - could be the first psychedelic drug approved for a neuropsychiatric disease. 🧬 Bristol Myers Squibb's KarXT for schizophrenia - set to be the first new class in decades. 🎯 Daiichi Sankyo US & AstraZeneca's Dato-DXd for non-small cell lung cancer - aiming to join the elite ADC club. Stay tuned for these exciting developments! 🌟 #Biotech #FDA #Innovation #Healthcare https://lnkd.in/eR998NUX

Genprex begins patient dosing in phase 2a expansion of Acclaim-1 study of Reqorsa Therapy in combo with Tagrisso to treat NSCLC

Dual-Target CAR T-Cell Therapy Shows Promise for SLE in Small Trial: 📚 A small Phase 1 study of dual-target CAR T-cell therapy from iCell Gene Therapeutics has shown promising results for systemic lupus erythematosus (SLE). This innovative treatment led to medication-free disease remission and improved kidney function in lupus nephritis (LN) patients. The study details are published in the Annals of the Rheumatic Diseases. Read more at: https://lnkd.in/dtyDPUz2

Patients with #lungcancer face a high risk of venous #thromboembolism, especially with advanced stages, metastatic disease and certain gene mutations. COMPASS-CAT score effectively predicts VTE risk in these patients. Read again one of our best article!

#Genetictesting in #kidneytransplantation helped develop a morbidity gene panel for evaluation of kidney transplant recipients. Our recent study found that in 9.1% of kidney transplant recipients, genetic analysis revealed monogenic disorders associated with issues like heart disease and cancer. This discovery has important clinical implications. By incorporating genetic diagnostics into transplant care, we can tailor personalized management strategies for both pre- and post-transplant phases. It's a promising step towards improving outcomes and ensuring better care for transplant recipients. Columbia University Irving Medical Center #CPMG #PersonalizedMedicine https://lnkd.in/ek-du26t

Expanding Treatment Horizons for Sickle Cell Disease: Barriers, Innovations, and Future Directions: Treatment advancements highlight the curative potential of bone marrow transplants and emerging gene therapies. #finance #pharmacy #lifesciences

T cells are essential in the adaptive immune response, and there is particular interest in genetically engineering these cells for therapy against cancer and other diseases. STEMCELL Technologies provides tools for a complete #Tcell workflow—from cell sourcing and isolation, to gene editing, expansion, and analysis—helping you move your research forward with confidence. #Immunology #CellTherapy https://lnkd.in/gBUbWSYP

Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid Cancer https://lnkd.in/efNa-b3T

Day 4 of celebrating good news in cell and gene therapies: Promising study using HER2 targeting CAR-T to treat glioblastoma (the most common and aggressive malignant primary brain tumor in adults) conducted by a Chinese research group at Second Hospital of Dalian Medical University. With positive results in both in vitro and in vivo mouse models, while still far from the clinic, this can be a potentially curative treatment for glioblastoma which currently has a five-year survival rate of roughly 10%, with a median of 15- to 18-month survival after diagnosis. CAR-T may be able change that for patients in a few years' time. Very exciting piece of research! 🎉 https://lnkd.in/dKbrf738 #CGT #celltherapies #genetherapies #celebrate #monthofCGTcelebrations

[Clinical Trials] Novo Nordisk's Semaglutide Shows Groundbreaking Success in Slowing CKD Progression in Type 2 Diabetics https://lnkd.in/ge7KB2Z7 REGENXBIO Inc.'s phase I/II Trial Shows Positive Interim Results for Duchenne Muscular Dystrophy Gene Therapy RGX-202 https://lnkd.in/gfh_4BQE EXONATE LIMITED's EXN407 Eye Drops Show Early Success in Treating Retinal Disease in Patients with Diabetes: phase Ib/IIa Trials Reveal Safety and Efficacy https://lnkd.in/gYQBdyUx Alnylam Pharmaceuticals's Zilebesiran Shows Promise in KARDIA-2 Study for Hypertension Control with Biannual Dosing https://lnkd.in/gG2VHZEg Promising Early Results for BioInvent International AB's BI-1206 Antibody in phase 1 Trial with Rituximab for Refractory Indolent Non-Hodgkin Lymphoma https://lnkd.in/gzHFXqd5 [Deals] Fibrocor Therapeutics Partners with McQuade Center to Advance FIB918 for Alport Syndrome https://lnkd.in/gFgwmMHP